Skip to main content
SpringerLink
Log in

Relapse: Surgical Considerations and Secondary Cytoreduction

  • Chapter
  • First Online:
Book cover Management of Gynecological Cancers in Older Women

  • 723 Accesses

Abstract

This chapter focuses on the survival benefit, selection criteria, and morbidity and mortality associated with secondary cytoreduction for recurrent ovarian cancer in the general population and the elderly. The goal of secondary cytoreduction is to improve overall survival by maximizing surgical tumor eradication in patients who demonstrate a complete clinical response to initial platinum-based chemotherapy. Retrospective studies consistently demonstrate a survival benefit associated with maximal secondary cytoreduction. Patient selection criteria should be individualized based on the patient’s life goals, comorbidities and performance status, and availability of adjuvant therapy. Morbidity and mortality rates are comparable to those associated with primary cytoreduction. The role of secondary cytoreduction in the geriatric population is still evolving. In general, elderly are less likely to receive standard treatment for ovarian cancer, but research suggests that secondary cytoreduction can be both safe and feasible and advanced age alone should not be a contraindication to surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212–36.

    Article  PubMed  Google Scholar 

  2. Rubin SC, Hoskins WJ, Benjamin I, Lewis JL. Palliative surgery for intestinal obstruction in advanced ovarian cancer. Gynecol Oncol. 1989;34(1):16–9.

    Article  PubMed  CAS  Google Scholar 

  3. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 1992;47(2):159–66.

    Article  PubMed  CAS  Google Scholar 

  4. Berek JS, Hacker NF, Lagasse LD, Nieberg RK, Elashoff RM. Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gynecol. 1983;61(2):189–93.

    PubMed  CAS  Google Scholar 

  5. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol. 2009;112(1):265–74.

    Article  PubMed  Google Scholar 

  6. Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer. 2000;88(1):144–53.

    Article  PubMed  CAS  Google Scholar 

  7. Scarabelli C, Gallo A, Carbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol. 2001;83(3):504–12.

    Article  PubMed  CAS  Google Scholar 

  8. Chi DS, McCaughty K, Diaz JP, Huh J, Schwabenbauer S, Hummer AJ, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006;106(9):1933–9.

    Article  PubMed  Google Scholar 

  9. Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13(12):1702–10.

    Article  PubMed  Google Scholar 

  10. Sehouli J, Richter R, Braicu EI, Bühling KJ, Bahra M, Neuhaus P, et al. Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients. J Surg Oncol. 2010;102(6):656–62.

    Article  PubMed  Google Scholar 

  11. Tebes SJ, Sayer RA, Palmer JM, Tebes CC, Martino MA, Hoffman MS. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol. 2007;106(3):482–7.

    Article  PubMed  Google Scholar 

  12. Tian WJ, Jiang R, Cheng X, Tang J, Xing Y, Zang RY. Surgery in recurrent epithelial ovarian cancer: benefits on survival for patients with residual disease of 0.1-1 cm after secondary cytoreduction. J Surg Oncol. 2010;101(3):244–50.

    PubMed  Google Scholar 

  13. Benedetti Panici P, De Vivo A, Bellati F, Manci N, Perniola G, Basile S, et al. Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Ann Surg Oncol. 2007;14(3):1136–42.

    Article  PubMed  Google Scholar 

  14. Frederick PJ, Ramirez PT, McQuinn L, Milam MR, Weber DM, Coleman RL, et al. Preoperative factors predicting survival after secondary cytoreduction for recurrent ovarian cancer. Int J Gynecol Cancer. 2011;21(5):831–6.

    Article  PubMed  Google Scholar 

  15. Meier W, Baumgartner L, Stieber P, Hasholzner U, Fateh-Moghadam A. CA125 based diagnosis and therapy in recurrent ovarian cancer. Anticancer Res. 1997;17(4B):3019–20.

    PubMed  CAS  Google Scholar 

  16. Santillan A, Garg R, Zahurak ML, Gardner GJ, Giuntoli RL, Armstrong DK, et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol. 2005;23(36):9338–43.

    Article  PubMed  Google Scholar 

  17. Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376(9747):1155–63.

    Article  PubMed  Google Scholar 

  18. Prayer L, Kainz C, Kramer J, Stiglbauer R, Schurawitzki H, Baldt M, et al. CT and MR accuracy in the detection of tumor recurrence in patients treated for ovarian cancer. J Comput Assist Tomogr. 1993;17(4):626–32.

    Article  PubMed  CAS  Google Scholar 

  19. Reuter KL, Griffin T, Hunter RE. Comparison of abdominopelvic computed tomography results and findings at second-look laparotomy in ovarian carcinoma patients. Cancer. 1989;63(6):1123–8.

    Article  PubMed  CAS  Google Scholar 

  20. Megibow AJ, Bosniak MA, Ho AG, Beller U, Hulnick DH, Beckman EM. Accuracy of CT in detection of persistent or recurrent ovarian carcinoma: correlation with second-look laparotomy. Radiology. 1988;166(2):341–5.

    PubMed  CAS  Google Scholar 

  21. Bristow RE, del Carmen MG, Pannu HK, Cohade C, Zahurak ML, Fishman EK, et al. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol. 2003;90(3):519–28.

    Article  PubMed  Google Scholar 

  22. Mansueto M, Grimaldi A, Mangili G, Picchio M, Giovacchini G, Viganò R, et al. Positron emission tomography/computed tomography introduction in the clinical management of patients with suspected recurrence of ovarian cancer: a cost-effectiveness analysis. Eur J Cancer Care (Engl). 2009;18(6):612–9.

    Article  CAS  Google Scholar 

  23. Buist MR, Golding RP, Burger CW, Vermorken JB, Kenemans P, Schutter EM, et al. Comparative evaluation of diagnostic methods in ovarian carcinoma with emphasis on CT and MRI. Gynecol Oncol. 1994;52(2):191–8.

    Article  PubMed  CAS  Google Scholar 

  24. Ricke J, Sehouli J, Hach C, Hänninen EL, Lichtenegger W, Felix R. Prospective evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer. Eur Radiol. 2003;13(5):943–9.

    PubMed  Google Scholar 

  25. Morris M, Gershenson DM, Wharton JT. Secondary cytoreductive surgery in epithelial ovarian cancer: nonresponders to first-line therapy. Gynecol Oncol. 1989;33(1):1–5.

    Article  PubMed  CAS  Google Scholar 

  26. Jänicke F, Hölscher M, Kuhn W, von Hugo R, Pache L, Siewert JR, et al. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer. 1992;70(8):2129–36.

    Article  PubMed  Google Scholar 

  27. Segna RA, Dottino PR, Mandeli JP, Konsker K, Cohen CJ. Secondary cytoreduction for ovarian cancer following cisplatin therapy. J Clin Oncol. 1993;11(3):434–9.

    PubMed  CAS  Google Scholar 

  28. Gadducci A, Iacconi P, Cosio S, Fanucchi A, Cristofani R, Riccardo Genazzani A. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol Oncol. 2000;79(3):344–9.

    Article  PubMed  CAS  Google Scholar 

  29. Oksefjell H, Sandstad B, Tropé C. The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer. Ann Oncol. 2009;20(2):286–93.

    Article  PubMed  CAS  Google Scholar 

  30. Eisenkop SM, Friedman RL, Wang HJ. Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study. Cancer. 1995;76(9):1606–14.

    Article  PubMed  CAS  Google Scholar 

  31. Zang RY, Li ZT, Tang J, Cheng X, Cai SM, Zhang ZY, et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer. 2004;100(6):1152–61.

    Article  PubMed  Google Scholar 

  32. Tay EH, Grant PT, Gebski V, Hacker NF. Secondary cytoreductive surgery for recurrent ­epithelial ovarian cancer. Obstet Gynecol. 2002;99(6):1008–13.

    Article  PubMed  Google Scholar 

  33. Salani R, Santillan A, Zahurak ML, Giuntoli RL, Gardner GJ, Armstrong DK, et al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer. 2007;109(4):685–91.

    Article  PubMed  Google Scholar 

  34. Bae J, Lim MC, Choi JH, Song YJ, Lee KS, Kang S, et al. Prognostic factors of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer. J Gynecol Oncol. 2009;20(2):101–6.

    Article  PubMed  Google Scholar 

  35. Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol. 1999;10 Suppl 1:87–92.

    Article  PubMed  Google Scholar 

  36. Harter P, Hahmann M, Lueck HJ, Poelcher M, Wimberger P, Ortmann O, et al. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol. 2009;16(5):1324–30.

    Article  PubMed  CAS  Google Scholar 

  37. Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer. 2011;21(2):289–95.

    Article  PubMed  Google Scholar 

  38. Tian WJ, Chi DS, Sehouli J, Tropé CG, Jiang R, Ayhan A, et al. A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann Surg Oncol. 2012;19(2):597–604.

    Article  PubMed  Google Scholar 

  39. Bristow RE, Peiretti M, Gerardi M, Zanagnolo V, Ueda S, Diaz-Montes T, et al. Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: operative technique and clinical outcome. Gynecol Oncol. 2009;114(2):173–7.

    Article  PubMed  Google Scholar 

  40. Cliby W, Dowdy S, Feitoza SS, Gostout BS, Podratz KC. Diaphragm resection for ovarian cancer: technique and short-term complications. Gynecol Oncol. 2004;94(3):655–60.

    Article  PubMed  Google Scholar 

  41. Woelber L, Jung S, Eulenburg C, Mueller V, Schwarz J, Jaenicke F, et al. Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer. Eur J Surg Oncol. 2010;36(6):583–8.

    Article  PubMed  CAS  Google Scholar 

  42. United States Census Bureau. http://www.census.gov/population/www/socdemo/age/older_2010.html. Accessed on 20 Oct 2011.

  43. Alphs HH, Zahurak ML, Bristow RE, Díaz-Montes TP. Predictors of surgical outcome and survival among elderly women diagnosed with ovarian and primary peritoneal cancer. Gynecol Oncol. 2006;103(3):1048–53.

    Article  PubMed  Google Scholar 

  44. Cloven NG, Manetta A, Berman ML, Kohler MF, DiSaia PJ. Management of ovarian cancer in patients older than 80 years of age. Gynecol Oncol. 1999;73(1):137–9.

    Article  PubMed  CAS  Google Scholar 

  45. Díaz-Montes TP, Zahurak ML, Giuntoli RL, Gardner GJ, Gordon TA, Armstrong DK, et al. Surgical care of elderly women with ovarian cancer: a population-based perspective. Gynecol Oncol. 2005;99(2):352–7.

    Article  PubMed  Google Scholar 

  46. Moore KN, Reid MS, Fong DN, Myers TK, Landrum LM, Moxley KM, et al. Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply? Gynecol Oncol. 2008;110(2):133–9.

    Article  PubMed  Google Scholar 

  47. Uyar D, Frasure HE, Markman M, von Gruenigen VE. Treatment patterns by decade of life in elderly women (> or =70 years of age) with ovarian cancer. Gynecol Oncol. 2005;98(3):403–8.

    Article  PubMed  Google Scholar 

  48. Chéreau E, Ballester M, Selle F, Rouzier R, Daraï E. Ovarian cancer in the elderly: impact of surgery on morbidity and survival. Eur J Surg Oncol. 2011;37(6):537–42.

    Article  PubMed  Google Scholar 

  49. Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. Am J Obstet Gynecol. 2007;197(6):676.e1–7.

    Article  Google Scholar 

  50. Thigpen T, Brady MF, Omura GA, Creasman WT, McGuire WP, Hoskins WJ, et al. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer. 1993;71(2 Suppl):606–14.

    PubMed  CAS  Google Scholar 

  51. Wright JD, Herzog TJ, Powell MA. Morbidity of cytoreductive surgery in the elderly. Am J Obstet Gynecol. 2004;190(5):1398–400.

    Article  PubMed  Google Scholar 

  52. Leitao MM, Kardos S, Barakat RR, Chi DS. Tertiary cytoreduction in patients with recurrent ovarian carcinoma. Gynecol Oncol. 2004;95(1):181–8.

    Article  PubMed  Google Scholar 

  53. Shih KK, Chi DS, Barakat RR, Leitao MM. Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: an updated series. Gynecol Oncol. 2010;117(2):330–5.

    Article  PubMed  CAS  Google Scholar 

  54. Burton E, Chase D, Yamamoto M, de Guzman J, Imagawa D, Berman ML. Surgical management of recurrent ovarian cancer: the advantage of collaborative surgical management and a multidisciplinary approach. Gynecol Oncol. 2011;120(1):29–32.

    Article  PubMed  Google Scholar 

  55. DESKTOP III. http://www.gcig.igcs.org/ClinicalTrials.html Accessed on 21 Oct 2011.

Download references

Author information

Authors and Affiliations

  1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California Irvine, Medical Center, 101 The City Drive, Building 56, Room 260, Orange, CA, 92868, USA

    Sara M. Jordan M.D. & Robert E. Bristow M.D., MBA

Authors
  1. Sara M. Jordan M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert E. Bristow M.D., MBA
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert E. Bristow M.D., MBA .

Editor information

Editors and Affiliations

  1. Memorial Sloan-Kettering Cancer Center, Commack Road, Commack, 11725, New York, USA

    Stuart M. Lichtman

  2. University of Liverpool, St Helens Teach, Marshalls Cross Road, St Helens, WA9 3DA, United Kingdom

    Riccardo A. Audisio

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag London

About this chapter

Cite this chapter

Jordan, S.M., Bristow, R.E. (2013). Relapse: Surgical Considerations and Secondary Cytoreduction. In: Lichtman, S., Audisio, R. (eds) Management of Gynecological Cancers in Older Women. Springer, London. https://doi.org/10.1007/978-1-4471-4605-6_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-4605-6_12

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-2215-9

  • Online ISBN: 978-1-4471-4605-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation